Research programme: pulmonary arterial hypertension therapies - Sagene

Drug Profile

Research programme: pulmonary arterial hypertension therapies - Sagene

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sagene Pharmaceuticals
  • Class
  • Mechanism of Action Monoamine oxidase B inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Pulmonary arterial hypertension

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in USA
  • 13 Sep 2011 Preclinical trials in Pulmonary hypertension in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top